Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pelargonium sidoides is a **medicinal herb native to southern Africa**, widely used in traditional medicine, primarily as a root extract, for its therapeutic potential in treating **respiratory tract infections** (such as acute bronchitis, common cold, rhinosinusitis, COPD) as well as gastrointestinal ailments like dysentery and diarrhea[1][3][5]. Modern phytopharmaceutical preparations, most notably EPs 7630, have undergone clinical trials demonstrating efficacy in reducing symptom severity and duration in acute bronchitis and other respiratory conditions[1][2][3][5]. The extract's main active compounds include **polyphenols (catechin), highly oxygenated coumarins (e.g., umckalin), proanthocyanidins, flavonoids, and gallic acid derivatives**[1][3][5]. The mechanism of action is believed to be primarily **immunomodulatory** (stimulation of natural killer cells, interferon-beta, and enhancement of phagocyte function), as well as **antiviral** and **antiadhesive** effects (inhibition of microbial/viral binding to host cells and suppression of neuraminidase enzyme activity)[1][3][5]. There is minimal direct antimicrobial activity, but the extract promotes host defense against pathogens[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pelargonium sidoides.